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monitored phone call for consent, or by mailing the consent.
Once we receive consent for tissue typing, then we proceed
with testing.
When a matched related donor is found, the Donor
Coordinator performs an information session prior to their
medical evaluation. This helps donors feel comfortable with
the donation and helps answer all of their logistical ques-
tions prior to seeing our clinical team.
Once cleared, the Donor Coordinator arranges for the
donors ﬁlgrastim injections to be given by a home healthcare
nurse.
Results/Conclusions: Our program has received great feed-
back from donors since we started the Donor Coordinator
position. We have been able to work through donor concerns
in a privatemanner.We have chosen not to test or use donors
based on their concerns and this position has helped with
family dynamics. Many of these steps have helped donors
feel that they are important in this process and has helped
them feel comfortable with the whole donation. We are in
the process of creating a survey to assess the donor’s expe-
rience with the Donor Coordinator, our medical team, and
the donation process.Figure 1. Current state521
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Introduction: Quick and effective communication regarding
information that is constantly evolving is a critical compo-
nent of quality patient care and safety. In order to improve
communication and ensure understanding regarding new/
revised policies and performance improvement initiatives, a
BMT quality newsletter and quiz tool was implemented.
Methods: From (09/2013) through (10/2014) a “Spotlight on
Quality” newsletter was electronically distributed to all staff
within the BMT Program, including MDs, RNs, BMT Co-
ordinators, Nurse Practitioners, Apheresis Staff, Hematology
Clinic Staff, Clinical Trials staff, Cell Therapy Lab staff, and
other ancillary/support roles. This newsletter allowed them
to receive education and updates regarding policy changes,
accreditation standards, staff recognition, departmental an-
nouncements, and quality projects/initiatives underway. The
newsletter also contained a “Quiz Egg” link that staff was
required to complete, allowing for standard documentation
of policy training while also having the ability to tabulate the
results and assess for general understanding of the changes
being introduced.
Results: Staff reported inclusive knowledge regarding BMT
Program initiatives and policy changes as also evidenced by a
72% mean quiz completion amongst BMT Quality Committee
members. Those departments that have taken the opportu-
nity to use the newsletter for communicating departmental
changes to the program felt well recognized and understood.
From a quality perspective, lack of understanding regarding a
policy change or initiative was gleaned from the quiz results
based upon the tabulation provided of % of correct responses
for each question. Lastly, staff expressed a greater willingness
to get involved in quality improvement opportunities when
they are well informed of initiatives.Conclusion: A consistent method of communication
distributed to the entire BMT Program has formalized pro-
grammatic changes and has placed quality initiatives at the
forefront while allowing for improved multidisciplinary
communication. Information is clearly communicated and
with the quiz tool, staff training and comprehension is
clearly measured.522
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Background: The University of Virginia Health System‘s
(UVA) mission is to be the safest place in health care for
patients and employees. The BE SAFE initiative outlines how
to identify problems related to patient and employee safety
via the A3 problem solving tool. A3 methodology is a Lean
process improvement system that standardizes workﬂows
by removing unnecessary or wasteful practices, thereby
increasing efﬁciency of healthcare delivery. In support of the
BE SAFE initiative, we examined our hematopoietic stem cell
transplant (HSCT) inpatient consultation process using our
electronic medical record (EMR) at UVA. Full implantation of
the EMR at UVA occurred in March 2011 using EPIC Hyper-
space software.
Methods: A multidisciplinary team including social worker,
ﬁnancial coordinator, quality coordinator, program admin-
istrator, physicians and transplant coordinators conducted
an audit of all inpatient HSCT consults requested from July
2013 to July 2014 examining the process from initial consult
to transplant workup. Algorithms were created in Microsoft
Visio to represent our current state and target state for the
consultation process. Through the A3 process, we identiﬁed
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clouds seen in Figure 1.
Results: Seventeen patients, with high risk malignancies (14
AML/MDS, 1 ALL), had an inpatient HSCT consult requested
during the twelve month timeframe. Approximately 77% of
consults experienced a connection violation resulting from
poor communication. Frequent problems identiﬁed included
failure to communicate the need for social work/ﬁnancial
screening, inability to view the consult order in EPIC, and the
HSCT team being unaware of potential transplant patients.
Patients were evaluated for transplant without insurance
veriﬁcations and psychosocial assessments leading to patient
dissatisfaction, transitions of care to other institutions, and
excess out of pocket costs.
Solution: Our working group designed a target workﬂow to
optimize communication. To implement target workﬂow, the
HSCT program collaborated with EPIC builders to create a
systems list, a consult patient list for the transplant program.
The systems list, implemented September 2014, captures all
consults ordered by inpatient staff allowing the members of
the HSCT program to monitor for new consults. In-service
educational sessions will be provided to all involved staff
beginning October 2014. The new processes will be reviewed
weekly for 4 weeks and monthly for the ﬁrst quarter allow-
ing for real-time interventions and corrections. Once the
target state is met, we expect increased cost containment
and decreased external transitioning of care, thereby
improving patient care and satisfaction.523
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Background: The Sarah Cannon Blood Cancer Network
(SCBCN) consists of 6 programs in the US performing over
850 HSCTs annually. In the fall of 2012, the SCBCN physician
leaders proposed development of standardized disease-
based BMT pathways. These included background informa-
tion on the diseases, indications for transplant and treatment
methods to be used. Anticipated beneﬁts included improved
quality and efﬁciency of transplantation throughout
network, improved data collection, and a better platform for
collaborative research amongst the programs. A Pathways
Committee was formed with representation from each pro-
gram including physicians, Pharm Ds, Clinical Nurse Spe-
cialists, and administrative support personnel.
Process: The committee scheduled twice monthly confer-
ence calls from January, 2013 through September, 2014 and
developed initial pathways. The physicians presented draft
pathways based upon expertise and clinical interest which
were then modiﬁed according to committee and evidence
review. Network experts were consulted as requested by the
committee. Once the draft pathways were completed they
were circulated to the 22 SCBCN program transplant physi-
cians for comment. Comments were collated and sent to the
committee for review for ﬁnal revisions.
Outcome: Twelve standardized BMT pathways resulted
from this process covering acute and chronic leukemias,lymphomas, myelodysplastic syndromes, multiple
myeloma, myeloproliferative syndromes, graft-versus-host
disease prophylaxis, and stem cell mobilization. Consensus
on the treatment pathways was readily achieved setting the
stage for further clinical and research collaboration. Final
versions of the pathways were published on the Sarah
Cannon SharePoint site for program access. SCBCN mem-
bers agreed to implement the pathways to guide BMT care.
Physicians may choose to treat a patient off-pathway but
must submit a variance form for tracking. Variances are
reviewed at the SCBCN quarterly Network Quality Com-
mittee Meeting.
Implementation of the pathways will require standard-
ized order sets be created and PharmDs from Network
programs are creating standardized order sets for each
pathway. Pathways will be built into the electronic BMT
Patient Management Software and variances tracked elec-
tronically.
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There is an increased need for the development of ap-
proaches to measure quality, costs and resource uti-
lization patterns among allogeneic hematopoietic cell
transplant (allo HCT) patients. Administrative claims data
provide comprehensive data for examining service utili-
zation and costs. However, because administrative data
are primarily designed for reimbursement purposes, many
challenges arise when using it for research. This is
particularly problematic when working with rare diseases
and procedures, as is the case with allo HCT. To examine
the costs and service utilization of allo HCT and chemo-
therapy for older patients with acute myeloid leukemia
(AML), a retrospective cohort study was designed using
the 2007-2011 Truven Health MarketScan Research
Database, a national multi-payer claims database that
contains costs paid for healthcare services. Using this
cohort, we demonstrate challenges in using claims data-
bases for allo HCT and propose some approaches to miti-
gate them. Using ICD-9 diagnosis codes, we identiﬁed
29,915 patients with AML in the dataset. From this cohort,
we focused on patients age  50 years and preliminarily
identiﬁed 468 allo HCT recipients and 6371 patients with
AML who did not receive an HCT. Figure 1 lists some of the
issues faced and our approach to address them. Utilizing
administrative claims data is both a science and an art.
Researchers need to make rational decisions based on
